Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Ascentage Pharma Group International ( (HK:6855) ).
Ascentage Pharma announced the presentation of new clinical data from two ongoing studies at the 2025 ASCO Annual Meeting. The studies involve lisaftoclax in blood cancers and alrizomadlin in solid tumors, both showing promising antitumor activity. The data supports further clinical development, potentially enhancing Ascentage Pharma’s position in the oncology market and offering new treatment options for patients.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for cancer, hepatitis B, and age-related diseases. The company specializes in apoptosis-targeted therapies, with key drug candidates including the Bcl-2 inhibitor lisaftoclax and the MDM2-p53 inhibitor alrizomadlin.
Average Trading Volume: 4,286,564
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.29B
Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.